Showing results (21-30 of 45) with videos related to
Sort By:
Pageof 5
Angiogenesis|May 24, 2021
Plasma levels of angiopoietin-2, VEGF-A, and VCAM-1 as markers of bevacizumab-induced hypertension: CALGB 80303 and 90401 (Alliance)Julia C F Quintanilha, Yingmiao Liu, Amy S Etheridge, et al.Cancers|July 12, 2025
Treatment Intensification Prior to Radical Prostatectomy for Clinically Localized Prostate CancerCarlos Jesus Perez Kerkvliet, Joon Yau Leong, Rasheed A M Thompson, et al.BMC Cancer|June 3, 2021
Integration of circulating tumor cell and neutrophil-lymphocyte ratio to identify high-risk metastatic castration-resistant prostate cancer patientsWeelic Chong, Zhenchao Zhang, Rui Luo, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 11, 2003
Dose escalation study of intravenous estramustine phosphate in combination with Paclitaxel and Carboplatin in patients with advanced prostate cancerWilliam Kevin Kelly, Andrew X Zhu, Howard Scher, et al.JNCI Cancer Spectrum|July 16, 2025
Unplanned hospitalization among advanced prostate cancer patients by diabetes status: a population-based studyAmy L Shaver, Krupa Gandhi, Scott W Keith, et al.Clinical Genitourinary Cancer|September 5, 2018
Multicenter Phase 2 Trial of Gemcitabine, Carboplatin, and Sorafenib in Patients With Metastatic or Unresectable Transitional-Cell CarcinomaMichael E Hurwitz, Paul Markowski, Xiaopan Yao, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 29, 2012
Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401William Kevin Kelly, Susan Halabi, Michael Carducci, et al.Cancer|August 6, 2013
The effect of prior androgen synthesis inhibition on outcomes of subsequent therapy with docetaxel in patients with metastatic castrate-resistant prostate cancer: results from a retrospective analysis of a randomized phase 3 clinical trial (CALGB 90401) (Alliance)Rahul Aggarwal, Susan Halabi, William Kevin Kelly, et al.European Urology|August 18, 2019
Mortality and Hospitalization Risk Following Oral Androgen Signaling Inhibitors Among Men with Advanced Prostate Cancer by Pre-existing Cardiovascular ComorbiditiesGrace Lu-Yao, Nikita Nikita, Scott W Keith, et al.The Oncologist|February 9, 2017
A Phase I/II Study of the Investigational Drug Alisertib in Combination With Abiraterone and Prednisone for Patients With Metastatic Castration-Resistant Prostate Cancer Progressing on AbirateroneJianqing Lin, Sheel A Patel, Ashwin R Sama, et al.Pageof 5